Matsudo, Japan, and Saluggia, Italy, April 21, 2011- Precision System Science, Co., Ltd (PSS) and DiaSorin S.p.A (DiaSorin, Saluggia, Italy) a global leader in the immunodiagnostics market, announced today that PSS and Biotrin International Ltd, a fully owned Irish subsidiary of DiaSorin, reached an agreement for the development of a Nucleic Acid Test (NAT) analyzer.
Under the agreement, PSS will develop the first generation analyzer, in collaboration with Biotrin using the LAMP (Loop Mediated Isothermal Amplification) technology, to be used in conjunction with a panel of Nucleic Acid Tests in the clinical area of infectious disease. Commercial launch is expected in the second half of next year.
Since July 2009, Biotrin has been the DiaSorin’s centre for the development and manufacture of molecular diagnostics products using the LAMP technology, licensed from Eiken Chemical Company Ltd in 2008. The first panel of applications will be in the field of infectious disease and onco-haematology, complementing to DiaSorin current extensive Liaison product offering in the field of immunodiagnostic. “This agreement , Carlo Rosa - DiaSorin CEO - said, is consistent with DiaSorin’s strategy to enter the rapidly developing market of molecular diagnostic in specialty clinical areas where DiaSorin can leverage on its existing strong presence, brand recognition and customer base.”
PSS understands that this agreement was realized as DiaSorin highly evaluated PSS’s instrumental expertise in molecular diagnostics. PSS will further develop automated instruments in various areas to expand genetic analysis and in vitro diagnostics.
About Precision Science Systems, Co., Ltd (PSS)
PSS, located at Matsudo, Japan, is a leading global provider of laboratory instruments for nucleic acid extraction. The company specializes in the development and production of automated instruments. As an original equipment manufacturer, PSS is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded as a maintenance and service company for clinical laboratory instruments in 1985, the company has manufacturing, research and development sites in Japan and maintains sales and service networks in the US and Europe. In the fiscal year ended June 30, 2010, PSS generated sales of ¥5.6 billion. Registered shares of PSS are traded on the JASDAQ under ticker code 7707.
For more information, please visit www.pss.co.jp.
About DiaSorin S.p.A.
DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.
For more information, please visit www.diasorin.com/